References
- AielloLPBruckerAJChangS2004Evolving guidelines for intravitreal injectionsRetina24131915076938
- ArevaloJFWuLSanchezJG2006Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathyProgram and abstracts of “Cannes Retina Festival”; the joint meeting of the American Society of Retina Specialists and European Vitreoretinal SocietySeptember 9–13213
- AveryRL2006Regression of retina and iris neovascularization after Intravitreal bevacizumab (Avastin) treatmentRetina26352316508438
- AveryRLPieramiciDJCastellarineAA2006Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathyProgram and abstracts of “Cannes Retina Festival”; the joint meeting of the American Society of Retina Specialists and European Vitreoretinal SocietySeptember 9–13139
- BakriSJSnyderMPulidoJS2006Pharmacokinetics of Intravitreal bevacizumab (Avastin)Program and abstracts of “Cannes Retina Festival”; the joint meeting of the American Society of Retina Specialists and European Vitreoretinal SocietySeptember 9–1377
- BeerPMWongSFalkNS2006Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two human subjectsProgram and abstracts of “Cannes Retina Festival”; the joint meeting of the American Society of Retina Specialists and European Vitreoretinal SocietySeptember 9–1377
- CaldwellRBBartoliMBehzadianMA2005Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stressCurr Drug Targets65112416026270
- ChewEY1999Major clinical trials of vitreoretinal diseasesRegilloCDBrownGCFlynHWVitreoretinal disease, the essentialsNew YorkTheme Medical Publishers Inc66777
- DavidorfFHMouserJGDerickRJ2006Rapid improvement of rubeosis from a single bevacizumab (Avastin) injectionRetina26354616508439
- ItakuraHKishiSKotajimaN2004Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomyOphthalmology11118808415465550
- IturraldeDSpaideRFMeyerleCB2006Intravitreal bevacizumab (Avastin) treatment for macular edema in central retinal vein occlusion: A short term studyRetina262798416508427
- [MDRSG] Macugen Diabetic Retinopathy Study Group2006Changes in retinal neovascularization following Pegaptanib (Macugen) therapy in diabetic individualsOphthalmology11323816343627
- MalikRALiCAzizW2005Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathyJ Cell Mol Med9692716202216
- ManzanoRPAPeymanGAKhanP2006Testing intravitreal toxicity of bevacizumab (Avastin)Retina262576116508423
- SpaideRFFisherYL2006Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhageRetina26275816508426
- [DRSRG] The Diabetic Retinopathy Study Research Group1976Preliminary reports on effects of photocoagulation therapyAm J Ophthalmol8138396944535
- [DRSRG] The Diabetic Retinopathy Study Research Group1981Photocoagulation treatment of proliferative diabetic retinopathy: Clinical applications of diabetic retinopathy study (DRS) findings, DRS report Number 8Ophthalmology885836007196564
- TolentinoMJMillerJWGragoudasES1996Intravitreal injection of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primateOphthalmology103182088942877
- TolentinoMJMcLeodDSToamotoM2002Pathological features of vascular endothelial growth factor-induced retinopathy in nonhuman primateAm J Ophthalmol1333738511860975
- Wilkinson-BerkaJL2004Vasoactive factors and diabetic retinopathy: Vascular endothelial growth factor, cycoloxygenase-2 and nitric oxideCurr Pharm Des1033314815544519